FR2460137A1 - Nouveau medicament a base d'alpha2-macroglobuline, sa preparation et son application - Google Patents
Nouveau medicament a base d'alpha2-macroglobuline, sa preparation et son application Download PDFInfo
- Publication number
- FR2460137A1 FR2460137A1 FR7917110A FR7917110A FR2460137A1 FR 2460137 A1 FR2460137 A1 FR 2460137A1 FR 7917110 A FR7917110 A FR 7917110A FR 7917110 A FR7917110 A FR 7917110A FR 2460137 A1 FR2460137 A1 FR 2460137A1
- Authority
- FR
- France
- Prior art keywords
- macroglobulin
- compositions according
- alpha2
- compositions
- exchange resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract description 11
- 108010088751 Albumins Proteins 0.000 title claims abstract description 11
- 108010074605 gamma-Globulins Proteins 0.000 title claims abstract description 8
- 230000008030 elimination Effects 0.000 title claims abstract description 6
- 238000003379 elimination reaction Methods 0.000 title claims abstract description 6
- 230000000840 anti-viral effect Effects 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 20
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 claims abstract description 17
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003729 cation exchange resin Substances 0.000 claims abstract description 9
- 239000003443 antiviral agent Substances 0.000 claims abstract description 6
- 239000008280 blood Substances 0.000 claims abstract description 6
- 210000004369 blood Anatomy 0.000 claims abstract description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 5
- 101000799972 Homo sapiens Alpha-2-macroglobulin Proteins 0.000 claims abstract description 3
- 102000049437 human A2M Human genes 0.000 claims abstract description 3
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 32
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 11
- 229920005989 resin Polymers 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 239000000644 isotonic solution Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 229920005654 Sephadex Polymers 0.000 claims description 3
- 239000012507 Sephadex™ Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 239000003957 anion exchange resin Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004051 gastric juice Anatomy 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 241000220304 Prunus dulcis Species 0.000 claims 1
- 235000020224 almond Nutrition 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 9
- 239000011780 sodium chloride Substances 0.000 abstract description 5
- 239000007858 starting material Substances 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 201000005505 Measles Diseases 0.000 abstract description 2
- 201000007100 Pharyngitis Diseases 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000008176 lyophilized powder Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 241001064231 Goat enterovirus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100038124 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010091268 alpha-Macroglobulins Proteins 0.000 description 1
- 102000018162 alpha-Macroglobulins Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000012461 cellulose resin Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 230000001492 haemagglutinating effect Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7917110A FR2460137A1 (fr) | 1979-06-29 | 1979-06-29 | Nouveau medicament a base d'alpha2-macroglobuline, sa preparation et son application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7917110A FR2460137A1 (fr) | 1979-06-29 | 1979-06-29 | Nouveau medicament a base d'alpha2-macroglobuline, sa preparation et son application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2460137A1 true FR2460137A1 (fr) | 1981-01-23 |
| FR2460137B1 FR2460137B1 (enExample) | 1982-11-26 |
Family
ID=9227381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7917110A Granted FR2460137A1 (fr) | 1979-06-29 | 1979-06-29 | Nouveau medicament a base d'alpha2-macroglobuline, sa preparation et son application |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2460137A1 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0119990A3 (en) * | 1983-03-16 | 1987-07-01 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Process for preparing therapeutically administerable plasma derivatives packed in ready-for-use containers |
| FR2609896A1 (fr) * | 1987-01-28 | 1988-07-29 | Bruttmann Georges | Nouvelles formes galeniques de gammaglobulines dites anti-inflammatoires pour administration par voie per- et sub-linguale |
| FR2609897A1 (fr) * | 1987-01-28 | 1988-07-29 | Bruttmann Georges | Nouvelles formes galeniques de gammaglobulines pour administration par voie per- et sub-linguale |
| EP0380422A1 (fr) * | 1989-01-27 | 1990-08-01 | Fondation Nationale De Transfusion Sanguine | Procédé de préparation de protéines inhibitrices de la lymphocytotoxicité et du complément et protéines obtenues |
| EP0401004A3 (en) * | 1989-06-01 | 1991-03-20 | Life Technologies Inc. | A composition for use in the treatment of fish material during the preparation of a processed fish product, to a method of preparing such a fish product and to an improved fish product |
| FR3119541A1 (fr) * | 2021-02-10 | 2022-08-12 | Marc Bonneau | Préparation, propriétés et applications de compositions médicamenteuses contenant des globulines sériques dotées d’activités antivirales |
-
1979
- 1979-06-29 FR FR7917110A patent/FR2460137A1/fr active Granted
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0119990A3 (en) * | 1983-03-16 | 1987-07-01 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Process for preparing therapeutically administerable plasma derivatives packed in ready-for-use containers |
| FR2609896A1 (fr) * | 1987-01-28 | 1988-07-29 | Bruttmann Georges | Nouvelles formes galeniques de gammaglobulines dites anti-inflammatoires pour administration par voie per- et sub-linguale |
| FR2609897A1 (fr) * | 1987-01-28 | 1988-07-29 | Bruttmann Georges | Nouvelles formes galeniques de gammaglobulines pour administration par voie per- et sub-linguale |
| EP0277895A1 (fr) * | 1987-01-28 | 1988-08-10 | Medibrevex Sa | Formes galéniques de gammaglobulines dites anti-inflammatoires pour administration par voie sub-linguale |
| EP0278876A1 (fr) * | 1987-01-28 | 1988-08-17 | Medibrevex Sa | Formes galéniques de gammaglobulines pour administration par voie sublinguale |
| EP0380422A1 (fr) * | 1989-01-27 | 1990-08-01 | Fondation Nationale De Transfusion Sanguine | Procédé de préparation de protéines inhibitrices de la lymphocytotoxicité et du complément et protéines obtenues |
| FR2642309A1 (fr) * | 1989-01-27 | 1990-08-03 | Fondation Nale Transfusion San | Procede de preparation de proteines inhibitrices de la lymphocytotoxicite et du complement et proteines obtenues |
| EP0401004A3 (en) * | 1989-06-01 | 1991-03-20 | Life Technologies Inc. | A composition for use in the treatment of fish material during the preparation of a processed fish product, to a method of preparing such a fish product and to an improved fish product |
| FR3119541A1 (fr) * | 2021-02-10 | 2022-08-12 | Marc Bonneau | Préparation, propriétés et applications de compositions médicamenteuses contenant des globulines sériques dotées d’activités antivirales |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2460137B1 (enExample) | 1982-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0275748B1 (fr) | Nouveaux dérivés peptidiques et leur application notamment en thérapeutique | |
| Sharma et al. | Involvement of nitric oxide in acute spinal cord injury: an immunocytochemical study using light and electron microscopy in the rat | |
| JP3100005B2 (ja) | ヒト免疫不全ウィルス感染・増殖抑制剤 | |
| WO2002003996A1 (en) | Use of dammarane-type tritepenoid saporins | |
| JPH03503635A (ja) | ヒトにおいて逆転写酵素を抑制するクマリン類 | |
| US4168303A (en) | Lyophilized native gamma globulin preparation for intravenous administration | |
| Kageyama et al. | Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins | |
| EP1962885A2 (fr) | Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament | |
| CA1157375A (fr) | Procede de preparation de concentres de complexe prothrombinique hautement purifies, et concentres obtenus | |
| FR2460137A1 (fr) | Nouveau medicament a base d'alpha2-macroglobuline, sa preparation et son application | |
| Bergamini et al. | Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells. | |
| FR2489690A1 (fr) | Procede d'obtention de la fraction ovomucoide et d'un extrait d'ovomucoide de l'oeuf de caille, produits ainsi obtenus et leur application a titre de medicament | |
| FR2679775A1 (fr) | Medicament a base de derives soufres neutralises. | |
| US6274557B1 (en) | Inhibition of nitric oxide synthase by amino acids and dipeptides | |
| FR2513640A1 (fr) | Procede de preparation d'une composition de gamma globuline qui convient pour l'administration intraveineuse et composition obtenue par ce procede | |
| JPS6322801A (ja) | Ｅｄｔａ不含のヘパリン、ヘパリン分画ならびに断片、それらの製造法及びそれらを含有する医薬品組成物 | |
| EP0282363B1 (fr) | Procédé d'obtention d'un concentré d'alpha 1-antitrypsine à partir d'une fraction de plasma humain et son utilisation à titre de médicament | |
| EP0242301B1 (fr) | Procédé de purification d'antigènes protéiques de bactéries appartenant au genre Bordetella, en vue de l'obtention d'un vaccin acellulaire | |
| EP0172045B1 (fr) | Glycoprotéines antitumorales, modifiées sur leurs motifs glucidiques, procédé d'obtention | |
| FR2608160A1 (fr) | Nouveaux derives peptidiques et leur application notamment en therapeutique | |
| Flippin et al. | Sulfapyridine and sulfathiazole therapy in pneumococcic pneumonia | |
| EP0698616B1 (fr) | Procédé de préparation d'un concentré d'inhibiteur de la C1-estérase (C1-INH), et concentré obtenu, à usage thérapeutique | |
| EP0185584B1 (fr) | Utilisation de l'hétéropolyanion (NaSb9W21086)18- pour fabriquer une composition pharmaceutique destinée à être utilisée dans le traitement du sida et des syndromes analogues | |
| FR2472609A1 (fr) | Procede pour separer la myeloperoxydase et composition pharmaceutique contenant de la myeloperoxydase | |
| Cherian et al. | In vitro glycation and acetylation (by aspirin) of rat crystallins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |